UnitedHealth Group (UNH)
(Delayed Data from NYSE)
$516.83 USD
-4.52 (-0.87%)
Updated May 23, 2024 04:00 PM ET
After-Market: $516.99 +0.16 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth F Momentum A VGM
Price, Consensus and EPS Surprise
UNH 516.83 -4.52(-0.87%)
Will UNH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for UNH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for UNH
Can Dow Jones ETFs Soar Even Higher After Hitting 40K Mark?
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: UnitedHealth, Danaher, Abbott and Ark Restaurants
UNH: What are Zacks experts saying now?
Zacks Private Portfolio Services
UnitedHealth Group (UNH) Stock Declines While Market Improves: Some Information for Investors
Top Stock Reports for UnitedHealth, Danaher & Abbott
Here's Why You Should Retain UnitedHealth Group (UNH) Stock
Other News for UNH
Health Is Wealth: 3 Healthcare Stocks Poised for Long-Term Growth
UnitedHealth Group: A Wonderful Business At A Discounted Price
State of Kansas Selects UnitedHealthcare to Serve Medicaid and Children’s Health Insurance Program Beneficiaries
Dividend Royalty: 3 No-Brainer Income Stocks With Strong Buy Ratings
Tracking Jeremy Grantham's GMO Capital Portfolio - Q1 2024 Update